Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05257473 · ClinicalTrials.gov registry record
Defining Endpoints in Becker Muscular Dystrophy
A clinical trial of Becker Muscular Dystrophy and Muscular Dystrophies, sponsored by Virginia Commonwealth University.
- Active
- Registry status
- 80
- Enrollment target
- 11
- Study locations
NCT05257473: Active study of Becker Muscular Dystrophy and Muscular Dystrophies, sponsored by Virginia Commonwealth University.
NCT05257473 is a study of Becker Muscular Dystrophy and Muscular Dystrophies that is active but no longer recruiting, run by Virginia Commonwealth University. The registered enrollment target is 80 participants, below the 1,389-participant average among 12 other Becker Muscular Dystrophy trials with a reported enrollment target (94% lower). The trial reports 11 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05257473, a study of Becker Muscular Dystrophy and Muscular Dystrophies, is active but no longer recruiting, sponsored by Virginia Commonwealth University.
- ACTIVE NOT RECRUITING
- Registry status
- 80 participants
- Enrollment target
- 11
- Study locations
Study Summary
This is a 24-month, observational study of 50 participants with Becker muscular dystrophy (BMD)
Primary Outcome
North Star Assessment for LGMD (NSAD: The NSAD is a functional scale specifically designed to measure motor performance in individuals with LGMD and is being evaluated in BMD due to the similar limb-girdle pattern of weakness. It consists of 29 items that are considered clinically relevant items from the adapted North Star Ambulatory Assessment and the Motor Function Measure 20 with a maximum score of 54 and higher scores indicate higher functional abilities.
Conditions Studied
Study Locations (11)
Other
- University of Auckland - Auckland
- John Walton Muscular Dystrophy Research Centre - Newcastle upon Tyne
California
- University of California, Irvine - Orange
Colorado
- University of Colorado Anschutz Medical Campus - Aurora
Iowa
- University of Iowa - Iowa City
Kansas
- University of Kansas Medical Center - Kansas City
Maryland
- Kennedy Krieger Institute - Baltimore
Minnesota
- University of Minnesota - Minneapolis
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2022-04-13 |
| Est. Completion | 2026-05 |
What the registry record for NCT05257473 still lists
NCT05257473 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 1,389-participant average among 12 other Becker Muscular Dystrophy trials with a reported enrollment target (94% lower).
The record links to 4 conditions, with Becker Muscular Dystrophy appearing as the primary indexed condition, and to 0 interventions.
NCT05257473 lists 11 locations in 10 states (Other, California, Colorado).
Frequently Asked Questions
What is clinical trial NCT05257473 about?
NCT05257473 is a clinical study titled "Defining Endpoints in Becker Muscular Dystrophy". This is a 24-month, observational study of 50 participants with Becker muscular dystrophy (BMD)
What is the current status of trial NCT05257473?
This trial is currently active not recruiting. The enrollment target is 80 participants. The study started on 2022-04-13. Estimated completion is 2026-05.
What conditions does trial NCT05257473 study?
This clinical trial studies the following conditions: Becker Muscular Dystrophy, Muscular Dystrophies, Muscular Dystrophy in Children, Muscular Dystrophy, Becker.
Who is sponsoring clinical trial NCT05257473?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05257473 being conducted?
This trial has 11 study locations across California, Colorado, Iowa, Kansas, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Becker Muscular Dystrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05257473's enrollment target sits among peer trials
80 7th of 12 higher than 6 of 12 other Becker Muscular Dystrophy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Becker Muscular Dystrophy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Duchenne Registry
RECRUITING
-
Biomarker Development for Muscular Dystrophies
RECRUITING
-
Magnetic Resonance Imaging and Biomarkers for Muscular Dystrophy
RECRUITING
-
CureDuchenne Link®: A Resource for Research
RECRUITING
-
Characterization of Clinical Skeletal and Cardiac Impairment in Carriers of DMD and BMD
ACTIVE NOT RECRUITING
-
Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI